NCI SBIR FY25 Contract Solicitation Webinar (PHS 2025-1)
Are you developing ground-breaking cancer technology? The newly released FY2025 SBIR Contract Solicitation can help propel your innovation toward commercialization. This opportunity provides early-stage funding to small businesses developing cancer technologies in priority areas identified by the National Cancer Institute.
Join the informational webinar on Thursday, August 22, 2024, from 2:00 p.m. to 3:30 p.m. ET for a detailed overview of the funding opportunity and discussion of this year's 13 NCI topics. A Q&A session between attendees and panelists will follow the presentation.
FY2025 SBIR Contract Solicitation topics include:
- NIH/NCI 466 - Novel Delivery Systems for RNA-based Cancer Vaccines
- NIH/NCI 467 - Development of Cancer Immunoprevention Agents
- NIH/NCI 468 - Synthetic Microbes (Excluding Oncolytic Viruses) for Immuno-Oncology Therapies
- NIH/NCI 469 - Development of Novel Therapeutics for HPV-related Precancer
- NIH/NCI 470 - Precision Nutrition Interventions to Reduce Cancer-Related Symptoms
- NIH/NCI 471 - Drug-Loaded Carrier Particles for Improved Oral Delivery for Colon Cancer Prevention
- NIH/NCI 472 - Antibody-Drug Conjugates as Radiopharmaceutical Theranostics for Cancer
- NIH/NCI 473 - Point of Care Detection of Antibodies Against HPV16/18 E6 and E7 Oncoproteins in Oropharyngeal Cancer
- NIH/NCI 474 - Point of Care Technologies for GI Cancer Prevention and Early Detection
- NIH/NCI 475 - Development of Digital Biomarkers and Endpoints for Clinical Cancer Care
- NIH/NCI 476 - Digital Twin Software for Optimization of Cancer Radiation Therapy
- NIH/NCI 477 - Wearable Technologies to Facilitate Remote Monitoring of Cancer Patients Following Treatment
- NIH/NCI 478 - Advanced Biomaterials to Improve Cancer Modeling for Research
The deadline to submit a proposal for this opportunity is Friday, October 18, 2024, at 5:00 p.m. ET. For more information, please visit the Current Contracts page or contact Tanya Renwick, contract analyst for the Office of Acquisitions, at [email protected].
